{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:10Z","timestamp":1792719850343,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.nrleng.2019.03.025","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T22:46:05Z","timestamp":1621982765000},"page":"390-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Calcitonin gene\u2013related peptide in migraine: from pathophysiology to treatment"],"prefix":"10.1016","volume":"37","author":[{"given":"S.","family":"Santos-Lasaosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Belv\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"D\u00edaz-Insa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gago-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Guerrero-Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Irimia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"L\u00e1inez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Leira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Porta-Etessam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"S\u00e1nchez del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Viguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2019.03.025_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1468-2982.1994.1405320.x","article-title":"Neuropeptides in migraine and cluster headache","volume":"14","author":"Edvisson","year":"1994","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11916-017-0618-8","article-title":"Neuropeptides as a marker for chronic headache","volume":"21","author":"Riesco","year":"2017","journal-title":"Curr Pain Headache Rep."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0015","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","article-title":"CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","volume":"54","author":"Cernuda-Moroll\u00f3n","year":"2014","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP levels in patients with chronic migraine","volume":"156","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Pain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0030","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0035","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/head.12026","article-title":"The evolution of a migraine attack: a review of recent evidence","volume":"53","author":"Charles","year":"2013","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/pme.12267","article-title":"Allodynia and descending pain modulation in migraine: a resting state functional connectivity analysis","volume":"15","author":"Schwedt","year":"2014","journal-title":"Pain Med."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0050","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","article-title":"The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine","volume":"158","author":"Iyengar","year":"2017","journal-title":"Pain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1177\/0333102415576723","article-title":"Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons","volume":"35","author":"Pozo-Rosich","year":"2015","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0060","article-title":"Calcitonin gene-related peptide modulates heat nociception in the human brain-an fMRI study in healthy volunteers","volume":"11","author":"Ashgar","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0065","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/awq224","article-title":"Modulation of nociceptive transmission with calcitonine gene-related peptide receptor antagonists in the thalamus","volume":"133","author":"Summ","year":"2010","journal-title":"Brain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jpain.2009.03.018","article-title":"Genetic enhacement of calcitonin gene-related peptide-induced centra sensitization to mechanical stimuli in mice","volume":"10","author":"Marquez de Prado","year":"2009","journal-title":"J Pain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0080","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during migraine headache","volume":"28","author":"Goadsby","year":"1990","journal-title":"Ann Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","article-title":"Clinical-biochemical correlates of migraine attacks with rizatriptan responders and non-responders","volume":"26","author":"Sarchielli","year":"2006","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0090","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0b013e31826170ce","article-title":"Endothelial progenitor cells: a new key for endothelial dysfunction in migraine","volume":"31","author":"Rodr\u00edguez-Osorio","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0095","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2010","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0100","first-page":"403","article-title":"CGRP as a neuropeptide in migraine: lessons from mice","volume":"80","author":"Russo","year":"2015","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.13211","article-title":"CGRP and PTX3 as predictors of efficacy of onabotulinumtoxin type A in chronic migraine: an observational study","volume":"58","author":"Dom\u00ednguez","year":"2018","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0333102414535111","article-title":"Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine","volume":"35","author":"Cernuda-Moroll\u00f3n","year":"2015","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0333102412447701","article-title":"Primary trigeminal afferents are the main source for stimulus-induced CGRP release into jugular vein blood and CSF","volume":"32","author":"Hoffman","year":"2012","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0120","article-title":"CGRP, amylin, immunology and headache medicine","author":"Taylor","year":"2018","journal-title":"Headache."},{"issue":"suppl 3","key":"10.1016\/j.nrleng.2019.03.025_bib0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0130","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine","volume":"350","author":"Olensen","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clpt.2004.10.001","article-title":"BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation","volume":"77","author":"Petersen","year":"2005","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","article-title":"Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial","volume":"51","author":"Connor","year":"2011","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0145","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"Marcus","year":"2014","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0150","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Eng J Med."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0155","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0160","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Efect of fremanezumab compared with placebo for prevention of episodic migraine. A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraines. The EVOLVE-1 randomized clinical trial","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0170","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia."},{"issue":"IS","key":"10.1016\/j.nrleng.2019.03.025_bib0175","first-page":"337","volume":"37","author":"Saper","year":"2017","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0180","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double blind, placebo-controlled REGAIN study","author":"Detke","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0185","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Eng J Med."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled phase IIIb study","author":"Reuter","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0195","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety or erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","author":"Ashina","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1533-2500.2012.00530.x","article-title":"Adherence with migraine prophylaxis in clinical practice","volume":"12","author":"Berger","year":"2012","journal-title":"Pain Pract."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.33588\/rn.5304.2011115","article-title":"Factores predisponentes al abandono del tratamiento preventivo en una serie de pacientes con migra\u00f1a","volume":"53","author":"Gracia-Naya","year":"2011","journal-title":"Rev Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0215","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0220","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14737175.2016.1200973","article-title":"Chronic migraine treatment: from OnabotulinumtoxinA onwards","volume":"16","author":"Negro","year":"2016","journal-title":"Expert Rev Neurother."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0225","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/WCO.0000000000000438","article-title":"Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies","volume":"30","author":"Mitsikostas","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0230","first-page":"16","article-title":"Comorbidities of migraine","volume":"1","author":"Wang","year":"2010","journal-title":"Front Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies-successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2377-11-94","article-title":"Refractory migraine headache","volume":"11","author":"Irimia","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0245","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1526-4610.2008.01135.x","article-title":"Refractory headache: Historical perspective, nedd, and purposes for an operational definition","volume":"48","author":"Schulman","year":"2008","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0250","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1526-4610.2008.01132.x","article-title":"Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society","volume":"48","author":"Schulman","year":"2008","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0255","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1526-4610.2010.01794.x","article-title":"Commentary from the Refractory Headache Special Interest Section on defining the pharmacologically intractable headache for clinical trials and clinical practice","volume":"50","author":"Schulman","year":"2010","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-012-0206-5","article-title":"Current concepts in refractory migraine","volume":"15","author":"Schulman","year":"2013","journal-title":"Curr Treat Options Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/head.12047","article-title":"Refractory migraine: a review","volume":"53","author":"Schulman","year":"2013","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0270","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1526-4610.2009.01370.x","article-title":"Defining refractory migraine: results of the RHSIS Survey of American Headache Society members","volume":"49","author":"Schulman","year":"2009","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0275","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1468-2982.2006.01173.x","article-title":"Towards a definition of intractable headache for use in clinical practice and trials","volume":"26","author":"Goadsby","year":"2006","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1129-2377-15-47","article-title":"Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation","volume":"15","author":"Martelletti","year":"2014","journal-title":"J Headache Pain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0285","first-page":"1","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","article-title":"Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design","volume":"18","author":"Serrano","year":"2017","journal-title":"J Headache Pain."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0295","article-title":"Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trig\u00e9mino y otras cefaleas primarias distintas de la migra\u00f1a cr\u00f3nica","author":"Santos-Lasaosa","year":"2017","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0300","article-title":"Evidencia y experiencia de Botox en migra\u00f1a cr\u00f3nica: Recomendaciones para la pr\u00e1ctica cl\u00ednica diaria","author":"Gago-Veiga","year":"2017","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.nrl.2016.04.017","article-title":"Gu\u00eda consenso sobre t\u00e9cnicas de infiltraci\u00f3n anest\u00e9sica de nervios pericraneales","volume":"32","author":"Santos-Lasaosa","year":"2017","journal-title":"Neurolog\u00eda."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s13311-018-0617-4","article-title":"Targeted CGRP small molecule antagonists for acute migraine therapy","volume":"15","author":"Holland","year":"2018","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0315","first-page":"666","article-title":"Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective","volume":"21","author":"Lipton","year":"2018","journal-title":"J Mede con."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0320","first-page":"1","article-title":"CER analysis of CGRP inhibitors for migraine prevention","volume":"807","year":"2018","journal-title":"PharmacoEcon Outcomes News."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0325","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0330","first-page":"130","article-title":"Randomized double-blind, placebo-controlled trial of ALD403 (eptinezumab), an anti-CGRP monoclonal antibody for the prevention of chronic migraine","volume":"57","author":"Smith","year":"2017","journal-title":"Headache."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0335","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frecuency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0340","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","article-title":"TEV-48125 for the preventive treatment of chronic migraine: Eficacy at early time points","volume":"87","author":"Bigal","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0350","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY29551742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0355","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial","volume":"75","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0360","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0333102417747230","article-title":"Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2b study","volume":"38","author":"Oakes","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0365","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","article-title":"Safety and efficacy of AMG-334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Sun","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nrleng.2019.03.025_bib0370","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580821000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580821000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:03:42Z","timestamp":1783695822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580821000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2173580821000675"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2019.03.025","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcitonin gene\u2013related peptide in migraine: from pathophysiology to treatment","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2019.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2019.03.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}